Drugs / VAK694
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01568762 | Oct 2010 → Jul 2011 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT01479595 | Feb 2012 → Feb 2015 | asthma | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT01018693 | Nov 2009 → Oct 2011 | seasonal allergic rhinitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00929968 | Jun 2009 → Feb 2011 | allergic rhinitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02494206 | Jul 2015 → May 2018 | breast cancer, lymphedema | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VAK694 | “they will be treated with QBX258 (VAK694 3mg/kg and QAX576 6mg/kg) delivered via peripheral intravenous injection once every 4 weeks (+ 1 week) for 4 treatments.” NCT02494206 ↗4“The planned dose of VAK694 (lyophilisate in vial, 150 mg/vial), was 3 mg/kg.” NCT01479595 ↗ |
| Route | Intravenous | “Multiple Intravenous Doses of VAK694” NCT00929968 ↗ |